Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12613001056785
Ethics application status
Approved
Date submitted
19/09/2013
Date registered
23/09/2013
Date last updated
26/02/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
Vildagliptin in type 1 diabetes mellitus added to insulin
Scientific title
A randomised, double-blind, parallel arm, placebo controlled trial to determine the effect of vildagliptin used in combination with insulin therapy on glycaemic variability in adults with type 1 diabetes mellitus of at least 2 years duration.
Secondary ID [1] 283256 0
CLAF237U06T
Universal Trial Number (UTN)
Trial acronym
VITAL
Linked study record

Health condition
Health condition(s) or problem(s) studied:
type 1 diabetes 290131 0
Glycamic variability 290132 0
Hypoglycaemia 290133 0
Condition category
Condition code
Metabolic and Endocrine 290518 290518 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Vildagliptin 50 mg twice daily ,orally will be added to usual insulin therapy for a period of 3 months with the comparator group receiving placebo. Adherence will be monitored by tablet return
Intervention code [1] 287989 0
Treatment: Drugs
Comparator / control treatment
This is a randomised double blind placebo controlled trial. Placebo will be a microcellulose tablet
Control group
Placebo

Outcomes
Primary outcome [1] 290542 0
Glycaemic variability. This will be assesed by continuous glucose monitoring and measurement of standard deviation of blood glucose levels over the period of one week
Timepoint [1] 290542 0
3 months
Secondary outcome [1] 304763 0
Post prandial blood glucose rise. This will be assessed by continuous glucose monitoring and mean glucose rise after meals
Timepoint [1] 304763 0
3 months
Secondary outcome [2] 304764 0
HbA1c. This will be measured by high-performance liquid chromatography (HPLC)
Timepoint [2] 304764 0
3 months
Secondary outcome [3] 304765 0
Insulin dose. This will be measured by patient diary
Timepoint [3] 304765 0
3 months
Secondary outcome [4] 304766 0
Body weight. This wil be measured at clinic visits using calibrated digital scales
Timepoint [4] 304766 0
3 months
Secondary outcome [5] 304767 0
CGMS glycaemic parameters. % time in normoglycaemia, hypoglycaemia and hyperglycaemia will be assesed from CGMS tracings
Timepoint [5] 304767 0
3 months
Secondary outcome [6] 304768 0
Effect of ultra sensitive c peptide as a measure of residual beta cell function on vildagliptin response. Ultra sensitive c peptide is available through Mercodia: Mercodia Ultrasensitive C-peptide ELISA
Timepoint [6] 304768 0
3 months
Secondary outcome [7] 304769 0
Effect of ultra sensitive c peptide on glycaemic variability. Correlation of c peptide with glycaemic variability will be assessed
Timepoint [7] 304769 0
Study initiation

Eligibility
Key inclusion criteria
Type 1 diabetes duration> 2 years
HbA1c 7.0% to 10.0%
MDI or CSII therapy
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Premix insulin regime
Type 2 diabetes
Severe hypoglycaemia in past 3 months
Pregnant, lactating or planning pregnancy

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation table generated by computer
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3 / Phase 4
Type of endpoint/s
Statistical methods / analysis
From CGM analyses obtained in people from this clinic who were on multiple insulin injections prior to commencing insulin pumps for treatment of type 1 diabetes, the change in SD was 0.2 mmol/L and the SD of the change in SD was 0.25. Average duration of diabetes was 16.1 years (range 4-28 years). For 80% power (2-sided calculation) with an alpha of 0.05 and assuming a difference between groups of 0.2, a minimum of 25 participants will be required in each arm of this trial (minimum total number 50 participants). To allow for screen failures and drop out rate between randomisation and 3 months (allow 20% extra), 60 participants will need to be screened.
In a previous study the percentage of patients who were C-peptide positive on the ultrasensitive C-peptide assay was 39.1% with duration of diabetes of 11-20 years.
Intention-to-treat analysis will be used for all randomised patients. The last observation will be carried forward in calculating the primary endpoint.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/12/2013
Actual
9/12/2013
Date of last participant enrolment
Anticipated
Actual
15/12/2016
Date of last data collection
Anticipated
6/04/2017
Actual
6/04/2017
Sample size
Target
72
Accrual to date
Final
72
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment postcode(s) [1] 7373 0
3004 - Melbourne

Funding & Sponsors
Funding source category [1] 288000 0
Commercial sector/Industry
Name [1] 288000 0
Novartis Pharmaceuticals Australia Pty Limited
Country [1] 288000 0
Australia
Primary sponsor type
Other
Name
BakerIDI Heart and Diabetes Institute
Address
75 Commercial Rd, Melbourne
VIC
3004
Country
Australia
Secondary sponsor category [1] 286722 0
None
Name [1] 286722 0
Address [1] 286722 0
Country [1] 286722 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 289925 0
The Alfred Research and Ethics Unit
Ethics committee address [1] 289925 0
Ethics committee country [1] 289925 0
Australia
Date submitted for ethics approval [1] 289925 0
23/09/2013
Approval date [1] 289925 0
28/10/2013
Ethics approval number [1] 289925 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 43102 0
A/Prof Neale Cohen
Address 43102 0
BakerIDI Heart and Diabetes Institute
Level 4, 99 Commercial Rd
Melbourne
VIC 3004
Country 43102 0
Australia
Phone 43102 0
+61385321800
Fax 43102 0
Email 43102 0
neale.cohen@bakeridi.edu.au
Contact person for public queries
Name 43103 0
Neale Cohen
Address 43103 0
BakerIDI Heart and Diabetes Institute
Level 4, 99 Commercial Rd
Melbourne
VIC 3004
Country 43103 0
Australia
Phone 43103 0
+61385321800
Fax 43103 0
Email 43103 0
neale.cohen@bakeridi.edu.au
Contact person for scientific queries
Name 43104 0
Neale Cohen
Address 43104 0
BakerIDI Heart and Diabetes Institute
Level 4, 99 Commercial Rd
Melbourne
VIC 3004
Country 43104 0
Australia
Phone 43104 0
+61385321800
Fax 43104 0
Email 43104 0
neale.cohen@bakeridi.edu.au

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.